Brief: Lantern Pharma Receives Notice Of Allowance For Composition Of Matter Patent Covering Drug Candidate Lp-284
13/04/2023 13:52
April 13 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA RECEIVES NOTICE OF ALLOWANCE FOR
COMPOSITION OF
MATTER PATENT COVERING DRUG CANDIDATE LP-284
* LANTERN PHARMA INC - EXPECTS RESULTING LP-284 PATENT WILL
BE
ORANGE BOOK-LISTABLE WITH AN ANTICIPATED EXPIRATION OF EARLY
2039
* LANTERN PHARMA INC - ANTICIPATES RECEIVING SIMILAR PATENT
RIGHTS
FOR LP-284 IN EUROPE, JAPAN, INDIA, CHINA, AUSTRALIA, CANADA,
AND KOREA
Source text for Eikon: ID:nBwb0w5xta
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments